Opinion|Videos|February 7, 2025
Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
Panelists discuss how isatuximab- and daratumumab-based quadruplet regimens compare in patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM), with a particular focus on minimal residual disease (MRD) negativity data from the IMROZ and CEPHEUS trials, presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do isatuximab-based regimens compare with daratumumab-based quadruplet regimens in patients with transplant-ineligible/deferred NDMM?
- Please comment on the latest results and approval from the IMROZ study evaluating Isa-VRd vs VRd in transplant-ineligible/deferred NDMM.
- What is the significance of MRD negativity as a primary outcome in studies presented at ASH 2024?
- CEPHEUS, MRD Negativity
- IMROZ, MRD Negativity
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5